Vaccination strategies to protect chickens from fowl adenovirus (FAdV)-induced diseases: A comprehensive review.

Autor: De Luca C; Clinic for Poultry and Fish Medicine, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine, Vienna, Austria. Electronic address: carlotta.deluca@vetmeduni.ac.at., Hess M; Clinic for Poultry and Fish Medicine, Department for Farm Animals and Veterinary Public Health, University of Veterinary Medicine, Vienna, Austria. Electronic address: michael.hess@vetmeduni.ac.at.
Jazyk: angličtina
Zdroj: Vaccine [Vaccine] 2025 Jan 01; Vol. 43 (Pt 1), pp. 126496. Date of Electronic Publication: 2024 Nov 09.
DOI: 10.1016/j.vaccine.2024.126496
Abstrakt: In recent years, fowl adenovirus (FAdV)-induced diseases became a global problem with considerable impact on chicken health and welfare. This has prompted numerous studies to focus on experimental immunization strategies using whole virus formulations (live or killed vaccines), some of them modified as recombinantly constructed vector vaccines. In addition, FAdV capsid proteins were frequently reported as immunizing antigens (subunit vaccines), with fiber proteins being amongst the most successful candidates. To date, there is no standardized protocol to assess vaccine efficacy in experimental FAdV protection studies, with the consequence that the experimental settings present several degrees of variations even when sharing similar premises. Differences in formulation preparations, route of inoculation, antigen dose, vaccination scheme, choice of challenge strain, or type and age of the birds are capable to greatly influence the magnitude of the immune response and the consequent protective efficacy, altogether addressing remaining challenges. Beyond the antigen composition of a vaccine, the epidemiology of FAdVs with the potential of vertical transmission of virus and/or antibodies from breeders to progenies has a substantial impact on protection strategies. The goal of this review is to outline a broad overview of the findings made thus far regarding immunization strategies against diseases associated to FAdV infections, considering the literature published since the appearance of hepatitis-hydropericardium syndrome (HHS) in the late Eighties, in order to emphasize the current knowledge on FAdV vaccines and highlight fields of future research and intervention.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: